GZ17-6.02

N/A

Report date: 2024/10/11 17:43:17
NME

Base Information

Drug NameGZ17-6.02
Drug Alias NameGZ17-6.02
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVirginia Commonwealth University
China Registration ClassN/A

Develop Information

Active CompaniesGenzada Pharmaceuticals Usa IncVirginia Commonwealth University
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[14] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A